Academic literature on the topic 'Enfermedad Renal Crónica-Trastorno Mineral y Óseo'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Contents
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Enfermedad Renal Crónica-Trastorno Mineral y Óseo.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Enfermedad Renal Crónica-Trastorno Mineral y Óseo"
Arboleya, Luis. "Trastorno mineral y óseo asociado a la enfermedad renal crónica." Reumatología Clínica 7 (September 2011): 18–21. http://dx.doi.org/10.1016/j.reuma.2011.05.006.
Full textArley Vargas, Diego Armando, and Ernesto Castro Aguilar. "Cinacalcet en el Trastorno Mineral Óseo en el Paciente con Enfermedad Renal Crónica en Diálisis y Prediálisis." Revista Clínica Escuela de Medicina UCR-HSJD 9, no. 5 (November 11, 2019): 1–7. http://dx.doi.org/10.15517/rc_ucr-hsjd.v9i5.38952.
Full textLuján Ramos, Marco Antonio, José Albeiro Ramírez Arce, Johanna Milena Acevedo Romero, Sebastián Gómez Jiménez, José Mario Cañas Osorio, David Santander Bohorquez, José Manuel Ustariz Durán, and Joaquín Rodelo Ceballo. "Prevalencia de las alteraciones del metabolismo óseo-mineral asociadas a enfermedad renal crónica no en diálisis." Revista Colombiana de Nefrología 6, no. 1 (February 1, 2019): 17. http://dx.doi.org/10.22265/acnef.6.1.311.
Full textCoronado Daza, Jorge Antonio. "Consenso colombiano de expertos sobre recomendaciones basadas en evidencia para el diagnóstico y tratamiento de alteraciones del metabolismo óseo y mineral en pacientes con enfermedad renal crónica." Revista Colombiana de Nefrología 8, no. 2 (August 10, 2021): e565. http://dx.doi.org/10.22265/acnef.8.2.565.
Full textSoutelo, Jimena, Elisa Del Valle, Liliana Andrade, Gustavo Laham, Daniela Wojtowicz, Andrea Sanmartino, and Marcelo Serrano. "CAPÍTULO 8: CALCIO-FÓSFORO Y ANEMIA EN DIFERENTES ESTADIOS DE ENFERMEDAD RENAL CRÓNICA." Revista de la Sociedad Argentina de Diabetes 58, no. 2Sup (July 11, 2024): 44–53. http://dx.doi.org/10.47196/diab.v58i2sup.791.
Full textKeilhauer Varona, Ana María, and Marco Antonio Peñalonzo Bendfeldt. "Nivel Promedio de Hormona Paratiroidea en Pacientes con Enfermedad Renal Crónica en estadios III a V, Unidad Nacional de Atención al Enfermo Renal Crónico." Revista de la Facultad de Medicina 1, no. 34 (July 28, 2023): 34–48. http://dx.doi.org/10.37345/23045329.v1i34.94.
Full textFernández Lara, Mª José, José Luis Ibarra Cornejo, Elena Viviana Aguas Alveal, Cesar Eduardo González Tapia, and Diego Galvarino Quidequeo Reffers. "Beneficios del ejercicio físico en pacientes con enfermedad renal crónica en hemodiálisis." Enfermería Nefrológica 21, no. 2 (June 26, 2018): 167–81. http://dx.doi.org/10.4321/s2254-28842018000200008.
Full textSalanova Villanueva, Laura, Carmen Sánchez González, José Antonio Sánchez Tomero, Abelardo Aguilera, and Esther Ortega Junco. "Enfermedad óseo mineral relacionada con la enfermedad renal crónica: Klotho y FGF23; implicaciones cardiovasculares." Nefrología 36, no. 4 (July 2016): 368–75. http://dx.doi.org/10.1016/j.nefro.2016.01.011.
Full textAquiles Jara, C. "Alteraciones del Metabolismo óseo y mineral en enfermedad renal crónica pre-diálisis." Revista Médica Clínica Las Condes 21, no. 4 (July 2010): 530–40. http://dx.doi.org/10.1016/s0716-8640(10)70568-x.
Full textElbert, Alicia, María Florencia Aranguren, Bárbara Arinovich, Teresa Bensusan, Fabiana Dávila, Guillermo De ́Marziani, Guillermo Dieuzeide, et al. "Jornadas del Comité de Nefropatía de la Sociedad Argentina de Diabetes Alteraciones electrolíticas y del metabolismo en pacientes con diabetes mellitus y enfermedad renal crónica. Parte 1." Revista de la Sociedad Argentina de Diabetes 56, no. 2 (August 1, 2022): 63–80. http://dx.doi.org/10.47196/diab.v56i2.526.
Full textDissertations / Theses on the topic "Enfermedad Renal Crónica-Trastorno Mineral y Óseo"
Escudero, Quesada Verónica. "Implicación pronóstica de las complicaciones vasculares, alteraciones del metabolismo óseo-mineral y nuevos marcadores biológicos en pacientes con enfermedad renal crónica avanzada." Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/370120.
Full textThis work is an in-depth analysis of cardiovascular damage parameters (vascular and valvular calcification, arterial stiffness and peripheral arterial disease) which has used different imaging and functional techniques. The study analyzes prospectively a cohort of CKD patients stage 4 and 5 not on dialysis with a follow-up of two years. Data are analyzed at baseline and after the two years of follow-up. Apart from vascular calcification analysis, the study has analyzed new biomarkers related to chronic kidney disease-mineral and bone disorders (CKD-MBD) whose prognostic significance has not clearly defined. The most relevant findings of the study were the presence of a high prevalence of cardiovascular calcification and arterial stiffness (measured by aortic pulse wave velocity) in chronic kidney disease stage 4 and 5 not on dialysis, and the fact that both parameters progress through after a two-years follow-up. These parameters, including its progression, have been associated with a worse cardiovascular prognosis, which is particularly novel in the case of progression of the pulse wave velocity. It has also been found that new biomarkers as soluble Klotho and inflammatory parameters as IL6, that are not used in routine practice, have shown to have predictive value for cardiovascular events in this population, data not previously found for soluble Klotho. On the other hand, IL6 it has been associated with severe coronary calcification in the study population, finding not previously reported in the literature. Finally the implications of FGF23 in the progression of coronary calcification during the follow-up study are also described. These findings have previously shown only in the dialysis population. The involvement of FGF23 in the development of events and renal progression is also described, as well as which factors are involved in the loss of its phosphaturic effect.
Prats, Valencia Merche. "Carboximaltosa férrica en el tratamiento de la anemia en pacientes con enfermedad renal crónica prediálisis: factores predictores de respuesta y efecto sobre la inflamación, moléculas de adhesión y metabolismo mineral óseo." Doctoral thesis, Universitat Rovira i Virgili, 2016. http://hdl.handle.net/10803/351953.
Full textEl tratamiento con hierro ev puede provocar inflamación, lesión endotelial e hipofosforemia, y no está bien establecido los posibles factores predictores de respuesta a este tratamiento. La carboximaltosa férrica (CMF) por sus características estructurales y estabilidad podría inducir menor toxicidad. Objetivo: Evaluar la eficacia de la CMF en pacientes con enfermedad renal crónica prediálisis (ERC-P), analizar los factores predictores de respuesta y su efecto sobre la inflamación, moléculas de adhesión y metabolismo mineral óseo. Material y métodos: Se incluyeron 47 pacientes con ERC-P y anemia por déficit de hierro a los que se les administró una dosis de 1 gramo de CMF, se evaluó su efecto de forma aguda, a las 3 semanas y 3 meses sobre los niveles de hemoglobina, ferritina, IST, PCR, interleucina 6 , ICAM, VCAM, calcio , fósforo, PTH, 1-25 dihidroxivitamina D y FGF23-c terminal, y se analizaron diversos factores predictores de respuesta incluyendo marcadores de oxidación ( LDL oxidada, grupos carbonilo, SODE, GPX y catalasa eritrocitarias). Resultados: Los niveles de hemoglobina, ferritina e IST aumentaron de forma significativa y un 72% de los pacientes fueron considerados respondedores (incrementos de Hb >1g/dL). La GPX fue el único factor predictivo de respuesta al tratamiento con CMF. No se apreciaron cambios significativos en los marcadores inflamatorios o endoteliales. Los niveles de fósforo y FGF 23 c-terminal disminuyeron significativamente y se mantuvieron bajos a los 3 meses del tratamiento, sin observarse modificaciones en los otros parámetros del metabolismo óseo mineral. Conclusiones: El 72% de los pacientes con ERC-P responden a la CMF, y la GPX tiene un valor predictivo en la respuesta a este tratamiento. La CMF no tiene efecto inflamatorio ni modifica los niveles de moléculas de adhesión endotelial. Esta molécula de hierro provoca hipofosforemia y un descenso en los niveles de FGF 23 c-terminal que persisten a los 3 meses del tratamiento.
Iv iron therapy can cause inflammation, endothelial injury and hypophosphatemia,and is not well established potential predictors of response to this treatment. The iron carboxymaltose (CMF) its structural features and stability could induce less toxicity. Aim: Evaluate the effectiveness of CMF in patients with pre-dialysis chronic kidney disease (CKD-P), analyze the predictors of response and its effect on inflammation, adhesion molecules and bone mineral metabolism factors. Methods: 47 patients with iron deficiency anemia and CKD-P included and received a dose of 1 gram of CMF, its effect is acutely evaluated at 3 weeks and 3 months on levels hemoglobin, ferritin, IST, PCR, interleukin-6, ICAM, VCAM, calcium, phosphorus, PTH, 1-25 dihydroxyvitamin D and FGF23c-terminal , and were analyzed predictors of response including oxidation markers (oxidized LDL, groups carbonyl, SODE, erythrocyte catalase and GPX). Results: The levels of hemoglobin, ferritin and IST increase significantly and 72% of patients were considered responders (Hb increase> 1 g / dL). GPX was the only predictor of response to treatment with CMF. No significant changes were observed in inflammatory or endothelial markers. Phosphorus levels and c-terminal FGF 23 decreased significantly and remained low at 3 months of treatment, with no observed changes in the other parameters of bone mineral metabolism. Conclusions: 72% of patients with CKD-P respond to CMF, and the GPX has a predictive value in the response to this treatment. The CMF has not inflammatory effect or modify the levels of endothelial adhesion molecules. This iron molecule causes hypophosphatemia and decreased levels of FGF 23 c-terminal persisting after 3 months of treatment.
Pérez, Sáez María José. "Enfermedad ósea en el paciente renal: avances epidemiológicos y diagnósticos." Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/400699.
Full textIn the present thesis, we developed the issue about bone and mineral disease related to chronic kidney disease (CKD), focusing in tow principal topics: • The epidemiology of hip fractures among CKD patients and the special consideration with the competing risks analysis. • The bone health assessment in long-term kidney transplant (KT) patients attending to different bone properties. Epidemiology of hip fractures in the setting of chronic kidney disease We performed a population-based cohort study in 873.073 patients in Catalonia, Spain, using a Primary Care database linked to Admission Hospital Registries and Mortality Registry. CKD diagnoses were extracted from International Code Disease 10 (ICD-10) registries found in the database, with a total CKD population of 32.934 subjects. We described the mortality as well as the attributable excess risk of hip fractures associated with CKD at the community level, both without and after accounting for a competing risk with death. We demonstrate that CKD is associated with an age and gender-adjusted 70% increased mortality, and with an increased risk of hip fracture. Fine and Gray models, which accounted for a differential mortality between groups (competing risk with death), showed an age and gender-adjusted 17% hip fracture excess risk related to CKD, whilst the widely used Cox models, which do not account for competing risk, demonstrated a 19% increased risk. This is equivalent to a 10.5% relative overestimation of the calculated excess risk of hip fractures. Interestingly, the effect size of this association is higher in younger (< 65 years old) patients, among whom CKD confers an age and gender-adjusted 2.3-fold higher risk when compared to CKD-free peers even after accounting for competing risk with death, that was also the highest among CKD patients compared to general population (Hazard Ratio 3.35 [Confidence Interval 95%, 2.80-4.01]. Bone assessment in long-term kidney transplant recipients We conducted a cross-sectional study in which we described bone status of long-term KT recipients, attending to different bone properties that confer bone resistance to the fracture as bone mineral density (BMD), microarquitectural disposition measured by trabecular bone score (TBS) and tissue quality determined by reference-point indentation (RPI). We compared the results with a cohort of healthy non-CKD patients. Forty KT patients showed a high prevalence of secondary hyperparathyroidism (parathormone >100 ng/ml) and vitamin D deficiency (20 pg/ml), despite long-term after KT (more than years) and a good kidney function (creatinine 1.5 ± 0.6 mg/dl). BMD was decreased vs. controls (n=94) in the three points assessed: lumbar spine (0.925 ± 0.15 vs. 0.982 ± 0.14; p=0.025), total hip (0.792 ± 0.14 vs. 0.902 ± 0.13; p<0.001) and femoral neck (0.667 ± 0.13 vs. 0.775 ± 0.12; p<0.001), while trabecular microarchitecture was comparable STO (1.21 ± 0.14 vs. 1.3 ± 0.15; p=0.072). In terms of bone quality, as measured by microindentation, KT recipients were not different from controls (79.1 ± 7.7 vs. 82.9 ± 7.8; p=0.145). Overall, these results show an almost complete normalization of bone long after KT, although some decrease in bone density and metabolic changes still remain. To our knowledge, this is the first study where a comprehensive assessment of bone health at different levels, from quantity to structure and tissue quality has been performed.
Books on the topic "Enfermedad Renal Crónica-Trastorno Mineral y Óseo"
Keith, Lierre. The vegetarian myth: Food, justice and sustainability. Crescent City, Ca: Flashpoint Press, 2009.
Find full textEl mito vegetariano: Comida, Justicia, Sostenibilidad. Capitán Swing Libros, 2018.
Find full textEl Mito Vegetariano: Alimento, justicia y sustentabilidad. FisicalBook, 2012.
Find full textGonder, Ulrike, ed. Ethisch Essen mit Fleisch: Eine Streitschrift über nachhaltige und ethische Ernährung mit Fleisch und die Missverständnisse und Risiken einer streng vegetarischen und veganen Lebensweise. Riva, 2021.
Find full textEl mito vegetariano: Comida, Justicia, Sostenibilidad. Capitán Swing Libros, 2018.
Find full textLe Mythe végétarien: Nourriture, justice et pérennité. Les Editions Pilule Rouge, 2013.
Find full textKeith, Lierre. Vegetarian Myth: Food, Justice, and Sustainability. PM Press, 2010.
Find full textEl Mito Vegetariano: Alimento, justicia y sustentabilidad. FisicalBook, 2012.
Find full textKeith, Lierre. Vegetarian Myth: Food, Justice, and Sustainability. PM Press, 2009.
Find full textKeith, Lierre. The Vegetarian Myth: Food, Justice, and Sustainability. ReadHowYouWant, 2013.
Find full text